Collectively, these results showed JQ1-related increase of not only AD-related Aβ, but also pathological Tau proteins, which will be useful to evaluate if JQ1 and molecules in its class can be a potential therapeutic for AD. The gene discussed is MAPT; the disease is Alzheimer disease.